All In Biotech

Drug Trial Radar · NCT05933577

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)

Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,089 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,089

Planned (sponsor's estimate)

Start

Jul 19, 2023

Primary completion

Oct 26, 2029

Study completion Sep 26, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
ModernaTX, Inc.
First posted
Jul 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.

Conditions

  • Melanoma

Interventions

  • Intismeran autogeneBiological

    IM injection

  • PembrolizumabBiological

    IV infusion

  • PlaceboOther

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-Free Survival (RFS)Time frame: Up to approximately 74 months

Locations

165 sites in 26 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group ( Site 1943)

    Springdale, Arkansas

  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1918)

    Los Angeles, California

  • UCSF Medical Center at Mission Bay ( Site 1929)

    San Francisco, California

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 1933)

    New Haven, Connecticut

  • Orlando Health Cancer Institute ( Site 1937)

    Orlando, Florida

  • Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 1945)

    Tampa, Florida

  • Winship Cancer Institute of Emory University ( Site 1940)

    Atlanta, Georgia

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 1950)

    Marietta, Georgia

  • University of Iowa-Holden Comprehensive Cancer Center ( Site 1935)

    Iowa City, Iowa

  • Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Melanoma ( Site 1912)

    Baltimore, Maryland

  • Massachusetts General Hospital ( Site 1927)

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center ( Site 1957)

    Boston, Massachusetts

  • Dana-Farber Cancer Institute ( Site 1956)

    Boston, Massachusetts

  • University of Michigan ( Site 1915)

    Ann Arbor, Michigan

  • Cancer and Hematology Centers of Western Michigan ( Site 1932)

    Grand Rapids, Michigan

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1944)

    Hackensack, New Jersey

  • Atlantic Health System ( Site 1925)

    Morristown, New Jersey

  • Valley Health Systems - Ridgewood Campus ( Site 1947)

    Ridgewood, New Jersey

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 1958)

    Mineola, New York

  • NYU Langone Health-Perlmutter Cancer Center ( Site 1917)

    New York, New York

  • Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 1908)

    New York, New York

  • Memorial Sloan Kettering Cancer Center ( Site 1914)

    New York, New York

  • University of North Carolina Medical Center-Lineberger Comprehensive Cancer Center ( Site 1949)

    Chapel Hill, North Carolina

  • Duke Cancer Institute ( Site 1911)

    Durham, North Carolina

  • Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 1905)

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center ( Site 1909)

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina-Hollings Cancer Center ( Site 1934)

    Charleston, South Carolina

  • Sanford Cancer Center ( Site 1951)

    Sioux Falls, South Dakota

  • SCRI Oncology Partners ( Site 1910)

    Nashville, Tennessee

  • Texas Oncology - Austin ( Site 1903)

    Austin, Texas

  • Texas Oncology - Dallas (Sammons) ( Site 1902)

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center ( Site 1920)

    Houston, Texas

  • Inova Schar Cancer Institute ( Site 1900)

    Fairfax, Virginia

  • Fred Hutchinson Cancer Center ( Site 1901)

    Seattle, Washington

  • Hospital Aleman ( Site 2200)

    Buenos Aires, Argentina

  • Sanatorio Finochietto ( Site 2205)

    Buenos Aires, Argentina

  • Clinica Adventista Belgrano-Oncology ( Site 2204)

    Caba., Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 2202)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Instituto Alexander Fleming-Alexander Fleming ( Site 2203)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Centro Privado de RMI Río Cuarto S.A. II ( Site 2201)

    Río Cuarto, Córdoba Province, Argentina

Showing 40 of 165 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.